Traditional approaches to androgen deprivation therapy.
Publication/Presentation Date
11-1-2011
Abstract
For most of the past 25 years, 1 of the favored approaches to treating prostate cancer has been the suppression of circulating testosterone with luteinizing hormone-releasing hormone (LHRH) agonists. LHRH agonists produce a downregulation of LHRH receptors and an uncoupling of the LHRH signal transduction mechanism. This leads to a marked reduction in the secretion of bioactive hormones stimulating testosterone production and eventual induction of a reversible, but transient and incomplete, state known as "selective medical hypophysectomy." The treatment with LHRH agonists has proved effective in many settings; however, the dosage and timing strategies depend critically on the patient's disease risk and progression. More recent investigations have suggested that a newer, quicker acting, pure gonadotropin-releasing hormone antagonist might be a preferable treatment approach. It remains a fundamental truth, however, that hormonal therapy is both overused and more toxic than generally appreciated. Therefore, a complete understanding of the indications and applications of this approach is essential for the practice of evidence-based medicine.
Volume
78
Issue
5 Suppl
First Page
485
Last Page
493
ISSN
1527-9995
Published In/Presented At
Moul, J. W., Evans, C. P., Gomella, L. G., Roach, M., 3rd, & Dreicer, R. (2011). Traditional approaches to androgen deprivation therapy. Urology, 78(5 Suppl), S485–S493. https://doi.org/10.1016/j.urology.2011.05.051
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
22054920
Department(s)
Administration and Leadership
Document Type
Article